HIV Drugs Market Report 2025

The HIV drugs market size has grown steadily in recent years. It will grow from $34.91 billion in 2024 to $36.41 billion in 2025 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to increased government support and initiatives, rise in healthcare expenditure, increase in HIV research and development spending, increased incidence of HIV infection, rise in awareness and economic growth in emerging markets.

The HIV drugs market size is expected to see steady growth in the next few years. It will grow to $42.34 billion in 2029 at a compound annual growth rate (CAGR) of 3.8%. The growth in the forecast period can be attributed to increased government support and initiatives, rise in healthcare expenditure, increase in HIV research and development spending, increased incidence of HIV infection, rise in awareness and economic growth in emerging markets. Major trends in the forecast period include investing in 3D bioprinting technology, new product innovations, developing multi-class combination products for HIV treatment and investing in strategic collaborations and agreements.

The global HIV drug market has experienced growth, fueled by the novel COVID-19 outbreak. HIV drugs are being repurposed to combat COVID-19 infections, with antiretroviral drugs such as lopinavir boosted with ritonavir (LPV/r) being evaluated and used in several countries for treating COVID-19 infections.

Growing awareness about the diagnosis and treatment of HIV is a significant factor driving the expansion of the HIV drug market. HIV/AIDS remains one of the most prevalent chronic diseases globally, leading to heightened awareness and understanding of the condition. For instance, in July 2024, the United Nations International Children's Emergency Fund (UNICEF), a U.S.-based humanitarian aid organization, reported that in 2023, approximately 40 million people were living with HIV worldwide, including 2.38 million children aged 0-19. Each day in 2023, around 685 children were newly infected with HIV, and approximately 250 children died from AIDS. Consequently, the increasing awareness surrounding HIV diagnosis and treatment is a crucial driver for the growth of the HIV drug market.

The anticipated increase in government spending is poised to drive the growth of the HIV drugs market in the future. Government spending, also referred to as public spending or government expenditure, encompasses the total funds allocated by a government to finance its various functions, programs, and services. Elevated government funding contributes to diverse aspects of the HIV drug market, spanning research and development, enhancing access and awareness, and mitigating the societal and economic impact of the disease. Such investments play a pivotal role in fostering the market's expansion and overall efficacy in combating the HIV or AIDS pandemic. As an illustration, in March 2023, the US government's Budget of the U.S. Government report revealed that Joe Biden's Fiscal Year (FY) 2024 budget proposal allocated $850 million in funding for the CDC, HRSA, IHS, and NIH to support and expand the implementation of the Ending the HIV Epidemic in the U.S. initiative. This marked a substantial increase of $277 million (48%) compared to the funding level enacted in FY23. Hence, increased government spending is a driving force behind the growth of the HIV drug market.

Leading companies in the HIV drugs market are establishing strategic partnerships to manufacture Lenacapavir, aiming to accelerate drug development, enhance access to treatments, and strengthen their presence in the global market. Lenacapavir is a first-in-class HIV-1 capsid inhibitor that effectively works in combination with other antiretrovirals, targeting multiple stages of the HIV lifecycle, making it a promising option for patients with limited treatment choices. For instance, in August 2023, Dr. Reddy's Laboratories and Hetero, both based in India, formed a partnership with Gilead Sciences Inc. This collaboration aims to manufacture and distribute Lenacapavir in 120 primarily low- and lower-middle-income countries (LMICs). The initiative is designed to broaden access to this innovative treatment, which is especially beneficial for heavily treatment-experienced patients with multi-drug-resistant HIV. Gilead Sciences Inc. is a biopharmaceutical company based in the U.S.

Major companies in the HIV drugs market are innovating by introducing new products, such as drugs for multi-drug resistant HIV, aiming to cater to larger customer bases, increase sales, and boost revenue. Drugs for multi-drug resistant HIV (MDR-HIV) are designed specifically to treat HIV infections in individuals who have developed resistance to multiple classes of antiretroviral drugs. As an example, in December 2022, Gilead Sciences Inc., a US-based pharmaceutical company, announced FDA approval for Sunlenca (lenacapavir). This medication, with a multi-stage mode of action, distinguishes itself from recently approved antiviral agent classes. It has no known in vitro cross-resistance to other existing medication classes. Sunlenca provides a new, twice-yearly therapy option for adults with HIV not adequately controlled by their current medication regimen. Lenacapavir serves as the foundation for Gilead's upcoming HIV treatments, offering a range of long-acting options to accommodate individual needs and preferences, potentially maximizing outcomes and reducing the burden of care.

Major companies operating in the HIV drugs market include Gilead Sciences Inc., Johnson & Johnson, Merck & Co. Inc., Boehringer Ingelheim International GmbH, Cipla, Aurobindo Pharma, AbbVie, Emcure Pharmaceuticals, Micro Labs Limited, Northeast Pharmaceutical Group Co. Ltd, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd, Strides Arcolab Limited, Hetero Labs Limited, Shanghai Desano Bio-pharmaceutical Co., Anhui Biochem Biopharmaceutical Co. Ltd., China's National Health Commission (NHC), Shanghai Xinxing Medicine Co. Ltd., China Meheco Xinxing Pharma Co. Ltd., CytoDyn Inc., Janssen Pharmaceutical, Bavarian Nordic, Roche Laboratories, Pharmstandard, Pharmasyntez, R-Pharm, Alium, ChemRar Group, Gritstone Oncology, Enzolytics Inc., BioClonetics Immunotherapeutics Inc., Dewpoint Therapeutics, Lyndra Therapeutics, Mylan N.V., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Teva Canada, ViiV Healthcare Canada, GSK, Abbott Laboratories, Aspen Pharmacare Limited, Pharmacare Ltd.

North America was the largest region in the HIV drugs market share in 2024. Middle East is expected to be the largest growing region in the global HIV drug market during the forecast period. The regions covered in the HIV drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the HIV drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

HIV drugs, also known as antiretroviral drugs, are commonly employed for the treatment of HIV. These medications play a crucial role in inhibiting the human immunodeficiency virus (HIV) or other retroviruses within the body, preventing their proliferation. Without treatment, HIV can lead to acquired immunodeficiency syndrome (AIDS), and while there is currently no highly effective cure, these drugs are essential in managing the condition.

The primary categories of HIV drugs include nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors, integrase inhibitors, fusion inhibitors, chemokine receptor inhibitors, and other variations. Nucleoside reverse transcriptase inhibitors (NRTIs) are structural nucleoside analogs of DNA nucleotides designed to hinder HIV-1 RT and impede viral replication by preventing the reverse transcription of the HIV genome. These drugs are typically administered through oral and parenteral methods and are made available through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others.

The HIV drugs market research report is one of a series of new reports that provides HIV drugs market statistics, including HIV drugs industry global market size, regional shares, competitors with an HIV drugs market share, detailed HIV drugs market segments, market trends and opportunities, and any further data you may need to thrive in the HIV drugs industry. This HIV drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The HIV drug market consists of sales of Tivicay, Triumeq, Truvada, and Vemlidy. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.